Prostate cancer metastatic
Not yet recruitingStudy of saruparib plus AR inhibitor drug combination in men with metastatic hormone‑sensitive prostate cancer previously treated with docetaxel or Lu‑PSMA and PSA ≥0.2 ng/mL
Study of saruparib plus AR inhibitor drug combination in men with metastatic hormone‑sensitive prostate cancer previously treated with docetaxel or Lu‑PSMA and PSA ≥0.2 ng/mL
- Disease:Prostate cancer metastatic
- Substances:Abiraterone AcetateDarolutamide+8
Germany- Participants:18–64 years · 65+ years
- Substances:Abiraterone Acetate
- Sponsor:Astrazeneca AB










